CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA ...
CureVac N.V.’s press release includes forward-looking statements about future events and results, such as potential vaccine efficacy, strategies, financing plans, and market growth. These statements are not guarantees and are subject to risks, including economic conditions, regulatory approval, competition, and the COVID-19 pandemic. The company does not update forward-looking statements and advises readers to consult SEC filings for further information.
Reference News
CureVac N.V.’s press release includes forward-looking statements about future events and results, such as potential vaccine efficacy, strategies, financing plans, and market growth. These statements are not guarantees and are subject to risks, including economic conditions, regulatory approval, competition, and the COVID-19 pandemic. The company does not update forward-looking statements and advises readers to consult SEC filings for further information.